Display options
Cite
Chen Q, Wang WJ, Jia YX, et al. Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review. Cell Biosci. 2021;11(1):86doi: 10.1186/s13578-021-00602-8.
Chen, Q., Wang, W. J., Jia, Y. X., Yuan, H., Wu, P. F., Ge, W. L., Meng, L. D., Huang, X. M., Shen, P., Yang, T. Y., Miao, Y., Zhang, J. J., & Jiang, K. R. (2021). Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review. Cell & bioscience, 11(1), 86. https://doi.org/10.1186/s13578-021-00602-8
Chen, Qun, et al. "Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review." Cell & bioscience vol. 11,1 (2021): 86. doi: https://doi.org/10.1186/s13578-021-00602-8
Chen Q, Wang WJ, Jia YX, Yuan H, Wu PF, Ge WL, Meng LD, Huang XM, Shen P, Yang TY, Miao Y, Zhang JJ, Jiang KR. Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review. Cell Biosci. 2021 May 13;11(1):86. doi: 10.1186/s13578-021-00602-8. PMID: 33985581; PMCID: PMC8120816.
Copy Download .nbib Format: NLM
Share it on

Cell Biosci. 2021 May 13;11(1):86. doi: 10.1186/s13578-021-00602-8.

Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review.

Cell & bioscience

Qun Chen, Wu-Jun Wang, Yun-Xuan Jia, Hao Yuan, Peng-Fei Wu, Wan-Li Ge, Ling-Dong Meng, Xu-Min Huang, Peng Shen, Tao-Yue Yang, Yi Miao, Jing-Jing Zhang, Kui-Rong Jiang

Affiliations

  1. Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, People's Republic of China.
  2. Nanjing Medical University, Nanjing, China.
  3. Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China.
  4. Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, People's Republic of China. [email protected].
  5. Nanjing Medical University, Nanjing, China. [email protected].
  6. Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, People's Republic of China. [email protected].
  7. Nanjing Medical University, Nanjing, China. [email protected].

PMID: 33985581 PMCID: PMC8120816 DOI: 10.1186/s13578-021-00602-8

Abstract

Pancreatic tumors are classified into endocrine and exocrine types, and the clinical manifestations in patients are nonspecific. Most patients, especially those with pancreatic ductal adenocarcinoma (PDAC), have lost the opportunity to receive for the best treatment at the time of diagnosis. Although chemotherapy and radiotherapy have shown good therapeutic results in other tumors, their therapeutic effects on pancreatic tumors are minimal. A multifunctional transcription factor, Yin-Yang 1 (YY1) regulates the transcription of a variety of important genes and plays a significant role in diverse tumors. Studies have shown that targeting YY1 can improve the survival time of patients with tumors. In this review, we focused on the mechanism by which YY1 affects the occurrence and development of pancreatic tumors. We found that a YY1 mutation is specific for insulinomas and has a role in driving the degree of malignancy. In addition, changes in the circadian network are a key causative factor of PDAC. YY1 promotes pancreatic clock progression and induces malignant changes, but YY1 seems to act as a tumor suppressor in PDAC and affects many biological behaviors, such as proliferation, migration, apoptosis and metastasis. Our review summarizes the progress in understanding the role of YY1 in pancreatic endocrine and exocrine tumors and provides a reasonable assessment of the potential for therapeutic targeting of YY1 in pancreatic tumors.

Keywords: Mutation; Pancreatic ductal adenocarcinoma; Pancreatic neuroendocrine tumor; Tumor suppressor; YY1

References

  1. Cancer Lett. 2016 Apr 28;374(1):127-135 - PubMed
  2. Surgery. 1991 Dec;110(6):998-1004; discussion 1004-5 - PubMed
  3. Mol Cancer Res. 2009 Feb;7(2):210-20 - PubMed
  4. PLoS One. 2013;8(3):e59679 - PubMed
  5. Pharmacol Ther. 2015 Jun;150:149-68 - PubMed
  6. Endocr Relat Cancer. 2018 May;25(5):L31-L35 - PubMed
  7. Oncogene. 2002 Jul 25;21(32):4997-5001 - PubMed
  8. Abdom Radiol (NY). 2018 Feb;43(2):404-414 - PubMed
  9. Theranostics. 2020 Mar 4;10(9):4183-4200 - PubMed
  10. F1000Res. 2012 Sep 21;1:15 - PubMed
  11. Crit Rev Oncog. 2017;22(1-2):23-36 - PubMed
  12. World J Gastroenterol. 2015 Jul 14;21(26):7988-8003 - PubMed
  13. N Engl J Med. 2014 Sep 11;371(11):1039-49 - PubMed
  14. Cell Res. 2017 Jul;27(7):916-932 - PubMed
  15. J Cell Mol Med. 2019 May;23(5):3464-3475 - PubMed
  16. Mol Cell Endocrinol. 2015 Mar 15;404:113-22 - PubMed
  17. Curr Opin Oncol. 2012 Jan;24(1):46-55 - PubMed
  18. Nucleic Acids Res. 1998 Aug 15;26(16):3776-83 - PubMed
  19. Mol Biol Rep. 2003 Mar;30(1):41-6 - PubMed
  20. Nat Rev Drug Discov. 2013 Dec;12(12):931-47 - PubMed
  21. Mol Genet Metab. 2004 Jul;82(3):255-9 - PubMed
  22. Crit Rev Oncog. 2011;16(3-4):211-26 - PubMed
  23. Mol Cell Biol. 1997 Jul;17(7):3723-32 - PubMed
  24. Mol Cell Biol. 2006 May;26(9):3565-81 - PubMed
  25. Int J Cancer. 2018 Apr 1;142(7):1392-1404 - PubMed
  26. Int J Cancer. 2017 Jul 15;141(2):231-241 - PubMed
  27. World J Gastroenterol. 2014 Aug 28;20(32):11241-8 - PubMed
  28. Crit Rev Oncog. 2011;16(3-4):143-61 - PubMed
  29. Eur J Endocrinol. 2013 Apr 24;168(6):R85-93 - PubMed
  30. J Cell Mol Med. 2010 Oct;14(10):2448-59 - PubMed
  31. J Biol Chem. 2019 Apr 12;294(15):6172-6187 - PubMed
  32. Horm Metab Res. 2017 Jun;49(6):452-456 - PubMed
  33. Cancer Lett. 2019 Oct 28;463:37-49 - PubMed
  34. Biochemistry. 2002 Jul 9;41(27):8657-64 - PubMed
  35. EMBO J. 1994 Mar 15;13(6):1460-6 - PubMed
  36. Int J Surg. 2016 Apr;28 Suppl 1:S142-55 - PubMed
  37. Mol Biol Rep. 2013 Aug;40(8):4913-20 - PubMed
  38. World J Gastroenterol. 2014 Aug 28;20(32):11142-59 - PubMed
  39. Drug Resist Updat. 2019 Mar;43:10-28 - PubMed
  40. CA Cancer J Clin. 2018 Jan;68(1):7-30 - PubMed
  41. Mayo Clin Proc. 1991 Jul;66(7):711-9 - PubMed
  42. Cancer Res. 2017 Jan 1;77(1):100-111 - PubMed
  43. Surg Clin North Am. 2019 Aug;99(4):793-814 - PubMed
  44. Nature. 2018 May;557(7705):351-358 - PubMed
  45. Science. 1993 Dec 17;262(5141):1889-92 - PubMed
  46. Mol Cancer Ther. 2012 Mar;11(3):572-81 - PubMed
  47. CA Cancer J Clin. 2013 Sep;63(5):318-48 - PubMed
  48. Int J Cancer. 2018 Aug 1;143(3):460-465 - PubMed
  49. Cancer Radiother. 2016 Sep;20 Suppl:S169-73 - PubMed
  50. Cancer J. 2017 Nov/Dec;23(6):315-320 - PubMed
  51. Endocr Res. 2011;36(1):35-43 - PubMed
  52. Intern Med. 2015;54(12):1519-22 - PubMed
  53. J Biol Chem. 2002 Mar 8;277(10):8382-7 - PubMed
  54. Cancer. 2008 Oct 1;113(7 Suppl):1807-43 - PubMed
  55. J Clin Endocrinol Metab. 2015 May;100(5):E776-82 - PubMed
  56. Clin Exp Immunol. 2019 Feb;195(2):226-236 - PubMed
  57. Nat Commun. 2017 Oct 3;8(1):767 - PubMed
  58. Neoplasia. 2002 May-Jun;4(3):185-90 - PubMed
  59. Pancreatology. 2016 Jan-Feb;16(1):10-3 - PubMed
  60. Pancreas. 2014 Jul;43(5):675-86 - PubMed
  61. Elife. 2018 Aug 03;7: - PubMed
  62. Cancer Treat Rev. 2018 Feb;63:40-47 - PubMed
  63. Autophagy. 2011 Aug;7(8):912-3 - PubMed
  64. Nitric Oxide. 2013 Feb 28;29:17-24 - PubMed
  65. Science. 2009 May 22;324(5930):1029-33 - PubMed
  66. Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1219-26 - PubMed
  67. Oncogene. 2012 Jan 5;31(1):116-27 - PubMed
  68. Hormones (Athens). 2016 Apr;15(2):157-169 - PubMed
  69. Pancreatology. 2021 Jan;21(1):236-239 - PubMed
  70. Horm Res. 1989;32(1-3):53-60 - PubMed
  71. Science. 2016 Apr 8;352(6282):227-31 - PubMed
  72. J Transl Med. 2017 Oct 19;15(1):211 - PubMed
  73. Clin Exp Metastasis. 2014 Apr;31(4):447-59 - PubMed
  74. Biochem Biophys Res Commun. 2007 Aug 3;359(3):491-6 - PubMed
  75. J Endocr Soc. 2020 Nov 05;5(1):bvaa171 - PubMed
  76. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9543-8 - PubMed
  77. J Invest Surg. 2018 Feb;31(1):54-66 - PubMed
  78. Ann Surg Oncol. 2012 Jul;19(7):2295-303 - PubMed
  79. Cell Cycle. 2009 May 1;8(9):1367-72 - PubMed
  80. Nat Commun. 2017 Feb 24;8:14437 - PubMed
  81. Asian Pac J Cancer Prev. 2015;16(14):5619-24 - PubMed
  82. Cancer J. 2017 Nov/Dec;23(6):333-342 - PubMed
  83. Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):4062-7 - PubMed
  84. Cell Death Dis. 2018 Feb 2;9(2):149 - PubMed
  85. J Clin Endocrinol Metab. 2016 Mar;101(3):1066-74 - PubMed
  86. In Vivo. 2020 Nov-Dec;34(6):3573-3582 - PubMed
  87. Cell Cycle. 2011 Oct 15;10(20):3466-72 - PubMed
  88. Cytokine. 2017 Oct;98:42-50 - PubMed
  89. Biochim Biophys Acta. 2000 Jun 21;1492(1):172-9 - PubMed
  90. Oncotarget. 2016 May 10;7(19):28498-509 - PubMed
  91. Nat Commun. 2013;4:2810 - PubMed
  92. PLoS One. 2013 Jul 10;8(7):e66121 - PubMed
  93. J Gastrointest Surg. 2017 Aug;21(8):1335-1341 - PubMed
  94. Oncogene. 2007 Jan 18;26(3):382-94 - PubMed
  95. Oncogene. 1994 Apr;9(4):1047-52 - PubMed
  96. Diabetes. 2017 May;66(5):1103-1110 - PubMed
  97. Hosp Pract (1995). 2016 Aug;44(3):109-19 - PubMed
  98. J Clin Oncol. 2016 Jul 20;34(21):2541-56 - PubMed
  99. Future Oncol. 2016 Aug;12(16):1929-46 - PubMed
  100. Mol Cancer Ther. 2012 Jul;11(7):1421-31 - PubMed
  101. J Gastroenterol. 2015 Jan;50(1):58-64 - PubMed
  102. Dev Cell. 2019 Oct 7;51(1):113-128.e9 - PubMed
  103. J Immunol. 2005 Aug 15;175(4):2174-83 - PubMed
  104. Neoplasia. 2004 Nov-Dec;6(6):744-50 - PubMed
  105. Cancer Lett. 2014 Jan 1;342(1):9-18 - PubMed
  106. Methods Cell Biol. 2016;134:431-61 - PubMed
  107. Genome Biol. 2005;6(4):R33 - PubMed
  108. Nan Fang Yi Ke Da Xue Xue Bao. 2016 Mar;36(3):361-4 - PubMed
  109. Cancer Lett. 2017 Nov 1;408:144-154 - PubMed
  110. EMBO Rep. 2018 Jan;19(1):18-28 - PubMed
  111. World J Gastroenterol. 2013 Feb 14;19(6):829-37 - PubMed
  112. Nat Rev Endocrinol. 2014 Mar;10(3):127 - PubMed
  113. Br J Cancer. 2019 Nov;121(11):912-921 - PubMed
  114. Pancreas. 2017 Mar;46(3):335-340 - PubMed
  115. Curr Cancer Drug Targets. 2015;15(2):145-57 - PubMed
  116. Medicine (Baltimore). 2019 Mar;98(11):e14576 - PubMed
  117. Future Oncol. 2015;11(5):853-64 - PubMed
  118. Anticancer Res. 2004 Jan-Feb;24(1):235-40 - PubMed
  119. Nat Rev Clin Oncol. 2010 Mar;7(3):163-72 - PubMed
  120. J Clin Transl Endocrinol. 2018 Dec 20;15:45-53 - PubMed
  121. J Natl Cancer Inst. 2013 Jul 17;105(14):1027-35 - PubMed
  122. Surg Clin North Am. 2018 Feb;98(1):113-125 - PubMed
  123. Mol Cancer. 2014 May 29;13:130 - PubMed
  124. Front Oncol. 2019 Nov 20;9:1230 - PubMed
  125. Annu Rev Cell Dev Biol. 2013;29:81-105 - PubMed
  126. Oncogene. 2006 Feb 23;25(8):1125-42 - PubMed
  127. J Immunol. 2001 Jul 1;167(1):75-81 - PubMed
  128. Cell Death Dis. 2020 Apr 27;11(4):294 - PubMed
  129. Ann Anat. 2019 Jan;221:115-124 - PubMed

Publication Types

Grant support